Characterisation of a protein or peptide brings valuable insight into its function. Irreplaceable in peptide analysis, Custom PepSet™ Peptide Libraries have distinct design varieties for targeting specific discoveries.

The Alanine Scan Library comprises a set of peptides with each sequential residue systematically replaced by alanine. These PepSets™ can be customised for expedient discovery of the most critical residues in the sequence.

Single Replacement Scan Peptide Library

While the Alanine Scan replaces each position with one amino acid, a SingleReplacement Scan Library cycles through every possible amino acid in one position. When screening the Single Replacement Scan PepSet™, increased or decreased activity will indicate the preferred or critical residue at the location.

Custom PepSets™

Mimotopes’ PepSet™ Peptide Libraries are fully customisable, with internal and terminal modifications available to optimise peptide efficiency. Biotinylation is a common choice for many assays requiring a mechanism of peptide capture.

Scanning Strategies

How the user decides to apply the Peptide Library is up to them. In general, peptides are measured for variations in bioactivity between them. The differences in otherwise identical Alanine Scan PepSet™ Peptide Library peptides will illuminate which crucial residues were disrupted by the alanine replacement. 

The degree of reduced activity can give an estimate for the relative importance of missing residues, and the most ideal residue can be confirmed with the Single Replacement Scan

Other Options

It doesn’t end with PepSet™ Peptide Libraries. Mimotopes also supplies individual Custom Peptides, with the same modifications that are available for PepSets™. Catalogue peptides, epitope mapping, and reagents are explained in more detail on our website. For antibody generation, assay services, and more, call and ask for a quote.

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

 useast@mimotopes.com

✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | Big Tech meets Big PharmaGo to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: ProceedixGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: SanofiGo to article: ILC Dover Go to article: NiproGo to article: ACG WorldwideGo to article: CommentGo to article: Covid-19 vaccine effectiveness affected by variantsGo to article: Immuno-oncology high prescriber survey reveals top R&D strategiesGo to article: Using methotrexate may reduce the negative impact of high treatment-related costGo to article: Protecting against fake Covid-19 vaccinesGo to article: Cytiva Company Insight Go to article: CytivaGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: In DepthGo to article: Is big pharma and big tech working together a recipe for success?Go to article: Logging in: how the pharma industry is getting to grips with social media Go to article: Medical cannabis: regulating a new export market on the Isle of ManGo to article: Long Covid: could chronic fatigue syndrome be taken seriously at last?Go to article: Life after Covid-19: four ways to prepare for the next pandemicGo to article: mRNA vaccines: the post-pandemic outlook after a breakthrough yearGo to article: Staving off AMR disaster with Ineos and the University of OxfordGo to article: Public benefit: could the PBC model help pharma balance profits and patients?Go to article: The Solubility Company Insight Go to article: The Solubility companyGo to article: ButterworthGo to article: MicronovaGo to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue